Clinical Evaluation of Dentin Replacement Materials in Posterior Composite Restorations

Registry ID
NCT07762651
Source registry
NCT
Status
ENROLLING_BY_INVITATION
Phase
NA
Study type
INTERVENTIONAL
Sponsor
Tanta University
Enrollment
30
Start date
2025-08-12
Completion date
2027-03-29
Last update
2026-08-13

Conditions

Summary

This randomized controlled clinical trial is designed to clinically evaluate and compare the performance of five dentin replacement materials used beneath posterior composite restorations.

Detailed description

Thirty patients ranging in age from 20 to 35 years will be enrolled into the study. This study will be designed as a randomized controlled clinical trial including patients requiring six Class I restorations. Participants will be randomly allocated into six groups according to the type of dentin replacement material used: Group I (Biodentin), Group II (Activa Bioactive), Group III (Glass ionomer cement), Group IV (Ever x posterior), and Group V (Flowable resin). Restorations will be placed following standardized cavity preparation and manufacturer instructions. Clinical evaluation will be performed at baseline and 6, 12, and 18 months using modified FDI criteria, assessing retention, marginal integrity, surface roughness, anatomical form, postoperative sensitivity, and secondary caries. Data will be collected and statistically analyzed

Interventions

Inclusion criteria

Inclusion Criteria: * Patients who are medically able to undergo routine dental restorative treatment. * Patients willing and able to provide written informed consent. * Patients with adequate oral hygiene and periodontal health for participation in the study. * Patients requiring posterior Class I restorations

Exclusion criteria

Exclusion Criteria: * Patients with systemic conditions that contraindicate routine dental treatment. * Patients unable or unwilling to provide informed consent. * Patients with poor compliance or inability to attend scheduled follow-up visits. * Teeth with clinical or radiographic evidence of irreversible pulpitis, pulp necrosis, or periapical pathology.

Primary outcomes

[{"measure":"marginal adaptation","timeFrame":"18 months"}]

Locations

Publications

Related clinical trials

View on source registry